This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Johnson, K. R. Articles by Fan, W. Search for Related Content PubMed PubMed Citation Articles by Johnson, K. R. Articles by Fan, W.

Antagonistic Interplay between Antimitotic and G₁-S Arresting Agents Observed in Experimental Combination Therapy¹

Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, South Carolina 29425

Paclitaxel is a naturally occurring antimitotic agent that has been shown to stabilize microtubules, induce mitotic arrest, and ultimately induce apoptotic cell death. The favorable clinical activity of paclitaxel has prompted considerable interest in combining paclitaxel with numerous other antineoplastic agents. Our previous studies have suggested 5-fluorouracil (5-FU), an antineoplastic agent that usually arrests tumor cells at the G₁-S phase of the cell cycle, in combination with paclitaxel significantly represses paclitaxel-induced mitotic arrest and apoptosis. In the present study, we have extended this investigation to include several other antimitotic agents (vinblastine, colchicine, and nocodazole) in various combination schedules with the G₁-S arresting agents 5-FU and hydroxyurea (HU). We found 5-FU, as well as HU, could significantly interfere with the overall cytotoxicity as compared with treatment with antimitotic agents alone. It appeared that 5-FU or HU severely limited the antimitotic agents’ cytotoxic effects on both mitotic arrest and apoptosis. No combination of a G₁-S arresting agent with an antimitotic agent in any schedule produced an antitumor effect greater than that of the antimitotic agent alone. In addition, biochemical examination revealed that 5-FU and HU blocked the antimitotic agent-induced increase of p21^WAF1/CIP1 protein levels, as well as prevented the hyperphosphorylation of the bcl-2 and c-raf-1 proteins. These findings suggest that careful considerations may be necessary when combining antineoplastic agents that exert their cytotoxic action at different phases of the cell cycle.

This article has been cited by other articles:

				A. A. Pandyra, R. Berg, M. Vincent, and J. Koropatnick Combination Silencer RNA (siRNA) Targeting Bcl-2 Antagonizes siRNA against Thymidylate Synthase in Human Tumor Cell Lines J. Pharmacol. Exp. Ther., July 1, 2007; 322(1): 123 - 132. [Abstract] [Full Text] [PDF]

				N. Kikuno, N. Moriyama-Gonda, T. Yoshino, T. Yoneda, S. Urakami, M. Terashima, M. Yoshida, H. Kishi, K. Shigeno, H. Shiina, et al. Blockade of Paclitaxel-Induced Thymidine Phosphorylase Expression Can Accelerate Apoptosis in Human Prostate Cancer Cells Cancer Res., October 15, 2004; 64(20): 7526 - 7532. [Abstract] [Full Text] [PDF]

				M. Sui, J. M. Dziadyk, X. Zhu, and W. Fan Cell Cycle-Dependent Antagonistic Interactions between Paclitaxel and {gamma}-Radiation in Combination Therapy Clin. Cancer Res., July 15, 2004; 10(14): 4848 - 4857. [Abstract] [Full Text] [PDF]

				K. Fujimoto-Ouchi, Y. Tanaka, and T. Tominaga Schedule Dependency of Antitumor Activity in Combination Therapy with Capecitabine/5'-Deoxy-5-fluorouridine and Docetaxel in Breast Cancer Models Clin. Cancer Res., April 1, 2001; 7(4): 1079 - 1086. [Abstract] [Full Text]

				S. Zeng, Y. Z. Chen, L. Fu, K. R. Johnson, and W. Fan In Vitro Evaluation of Schedule-dependent Interactions between Docetaxel and Doxorubicin against Human Breast and Ovarian Cancer Cells Clin. Cancer Res., September 1, 2000; 6(9): 3766 - 3773. [Abstract] [Full Text]

				Y. Huang, K. R. Johnson, J. S. Norris, and W. Fan Nuclear Factor-{{kappa}}B/I{{kappa}}B Signaling Pathway May Contribute to the Mediation of Paclitaxel-induced Apoptosis in Solid Tumor Cells Cancer Res., August 1, 2000; 60(16): 4426 - 4432. [Abstract] [Full Text]